PMA device
Supartz
Seikagaku Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Sep 10, 2004, newest Mar 31, 2015Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
772
Naming "Supartz"
MAUDE reports
0
Brand "Supartz", since 2015
PubMed studies
24
Mentioning "Supartz"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Supartz
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 3 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Supartz", any status and sponsor, newest update first.
- Hyaluronic Acid Barrier in ParotidectomyNot yet recruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT07941011 · 20 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 31, 2029
Device: Axoguard HA+ Nerve Protector · For: Parotidectomy, Patient-reported Outcomes; Parotid Cancer; Parotid Gland Tumor and 2 more
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
- Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human SkinActive, not recruiting
University of MichiganAcademic, hospital or other
NCT06195605 · 15 participants (planned) · Start May 9, 2024 · Primary completion Nov 2027
Device: Restylane-L; Vehicle · For: Photoaging
Sites: Ann Arbor, Michigan
769 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Supartz", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MOZ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Supartz"[tiab]. The summary above synthesizes these.
- Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?
Webner D, Huang Y, Hummer CD · Cartilage · 2021Research Support, Non-U.S. Gov't, Review
- A method for establishing class III medical device equivalence: sodium hyaluronate (GenVisc 850) for the treatment of knee osteoarthritis.
Doros G, Lavin PT, Daley M, et al. · Med Devices (Auckl) · 2016Review
- Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database.
Dasa V, DeKoven M, Sun K, et al. · Drugs Context · 2016
- Rheological Properties of Commercially Available Hyaluronic Acid Products in the United States for the Treatment of Osteoarthritis Knee Pain.
Nicholls M, Manjoo A, Shaw P, et al. · Clin Med Insights Arthritis Musculoskelet Disord · 2018
- Supartz (Sodium Hyaluronate) for the Treatment of Knee Osteoarthritis: A Review of Efficacy and Safety.
Bronstone A, Neary JT, Lambert TH, et al. · Clin Med Insights Arthritis Musculoskelet Disord · 2019Review
- Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis.
Altman RD, Dasa V, Takeuchi J · Cartilage · 2018Review
- Safety of Repeated Injections of Sodium Hyaluronate (SUPARTZ) for Knee Osteoarthritis: A Systematic Review and Meta-Analysis.
Bannuru RR, Brodie CR, Sullivan MC, et al. · Cartilage · 2016
- Patient-reported Outcomes of Short-term Intra-articular Hyaluronic Acid for Osteoarthritis of the Knee: A Consecutive Case Series.
Gusho CA, Jenson M · Cureus · 2019
- Biocompatibility study of different hyaluronan products for intra-articular treatment of knee osteoarthritis.
Yoshioka K, Katayama M, Nishiyama T, et al. · BMC Musculoskelet Disord · 2019
- Risk of Severe Acute Localized Reactions for Different Intraarticular Hyaluronic Acid Knee Injections in a Real-World Setting.
Ong KL, Farr J, Gudeman AS, et al. · Cartilage · 2021Research Support, Non-U.S. Gov't
- A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid.
Nicholls M, Manjoo A, Shaw P, et al. · Adv Ther · 2018Research Support, Non-U.S. Gov't
- Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee.
Curran MP · Drugs Aging · 2010Comparative Study, Review
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.